The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response

BACKGROUND: Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of clonal heterogeneity. Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Bordi, Paola, Rofi, Eleonora, Restante, Giuliana, Valleggi, Simona, Minari, Roberta, Crucitta, Stefania, Arrigoni, Elena, Chella, Antonio, Morganti, Riccardo, Tiseo, Marcello, Petrini, Iacopo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251035/
https://www.ncbi.nlm.nih.gov/pubmed/30397287
http://dx.doi.org/10.1038/s41416-018-0238-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251035/
https://www.ncbi.nlm.nih.gov/pubmed/30397287
http://dx.doi.org/10.1038/s41416-018-0238-z

Ejemplares similares